Bioniche launching more animal health products

Bioniche (ASX:BNC) has launched a new equine health product in the US, and added six more animal health products to its stable via a licensing deal with a contract manufacturer.

The biopharmaceutical company has launched Butequine Paste – designed to treat inflammatory conditions associated with the muscoloskeletal system in horses – into the US market.

Butequine paste, or phenylbutazone paste, is a proprietary Bioniche product. It is being produced by US-based contract manufacturer Med-Pharmex.

Bioniche global president of animal health Andrew Grant said based on its track record selling the product in its home Canadian market, “we expect US equine veterinarians to be very receptive to Butequine Paste, and we expect to see significant market penetration over the next two years.”

Bioniche has separately signed a deal with Med-Pharmex granting it the exclusive Canadian distribution rights to six animal health products.

These include dermal products for dogs and cats, an anti-diarrheal product for dogs, cats, horses and cattle, and nutritional supplements for calves.

Med-Pharmex will manufacture the products for Bioniche. Further terms of the distribution deal have not yet been disclosed.

Bioniche has been busy building up its staple of animal health products over the past several months. Last week, the company negotiated the rights to distribute equine probiotic MitoHorse from Imagilin Technology.

The company has also recently secured Australian distribution rights for four products from Modern Veterinary Therapeutics, started commercialising two of its own canine cancer products, and made early progress developing a cow fertility product using in-licensed rFSH technology.

Bioniche (ASX:BNC) shares were trading unchanged at $0.590 as of around 2pm on Tuesday.